此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项研究以了解安全海湾3389934的研究,其合适的剂量以及它如何影响败血症引起的凝血病的参与者

2026年11月9日 更新者:Bayer

首先,在患者中,剂量升级,开放标签研究,以研究对脓毒症诱导凝血病的患者的静脉输注3389934静脉输注的安全性,耐受性,药代动力学和药效学

Researchers are looking for a better way to treat people who have sepsis induced coagulopathy.

Sepsis happens when bacteria and their toxins spread in the blood, causing an infection. To overcome the infection the body responds activating the immune system, sometimes this immune response is too active and causes uncontrolled blood clot formation, also called sepsis-induced coagulopathy. Sepsis coagulopathy damages blood vessels and organs and leads to low platelet levels in the body. In severe cases, it can even lead to death.

The main purpose of this first in patient study is to learn about how safe BAY 3389934 is, its suitable dose, and how it affects the participants with sepsis induced coagulopathy. For this study, researchers will enroll people receiving treatment for sepsis induced coagulopathy in a hospital intensive care unit (ICU).

For this, the researchers will collect the number of participants with medical problems during and after receiving BAY 3389934. These medical problems are also known as "adverse events". Doctors keep track of all medical problems that happen in studies, even if they do not think they might be related to the study treatments.

Participants will be divided into 2 groups. The first group will receive the lowest starting dose of BAY3389934. The researcher will carefully monitor how the participant responds to the medication and may adjust the dose, either increasing or decreasing it based on the safety and the tolerability of the drug. If no serious side effects are reported from the first group, the second group will receive higher dose of BAY3389934.

Each participant will be in the study for around 28 days. During the study, the doctors and their study team will:

  • Take blood and urine samples,
  • Do physical examinations,
  • Check vital signs such as body temperature, blood pressure and heart rate,
  • Examine heart health using electrocardiogram (ECG)

研究概览

地位

招聘中

干预/治疗

研究类型

介入性

注册 (估计的)

36

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Bavaria
      • München、Bavaria、德国、81377
        • 尚未招聘
        • Klinikum der Universität München AöR - Klinik für Anaesthesiologie (Campus Großhadern)
    • North Rhine-Westphalia
      • Cologne、North Rhine-Westphalia、德国、51109
        • 尚未招聘
        • Kliniken der Stadt Köln gGmbH - Krankenhaus Merheim - Lungenklinik
    • Saxony
      • Dresden、Saxony、德国、01307
        • 招聘中
        • Universitaetsklinikum Carl Gustav Carus an der Technischen Universitaet Dresden | Medizinische Klinik I - FB Haemostaseologie
      • Leipzig、Saxony、德国、04103
        • 尚未招聘
        • Universitätsklinikum Leipzig AöR_Interdisziplinare Internistische Intensivmedizin
      • Liège、比利时、4000
        • 招聘中
        • Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman - Intensive Care
    • Antwerp
      • Edegem、Antwerp、比利时、2650
        • 尚未招聘
        • UZ Antwerpen - Intensive Care
    • Brussels Capital
      • Woluwe-Saint-Lambert、Brussels Capital、比利时、1200
        • 尚未招聘
        • Universite Catholique de Louvain (UCL) - Cliniques Universitaires Saint-Luc - Intensive Care
    • Walloon Brabant
      • Ottignies、Walloon Brabant、比利时、1340
        • 招聘中
        • Clinique Saint-Pierre d'Ottignies - Intensive Care
    • Centre-Val de Loire
      • Tours、Centre-Val de Loire、法国、37044
        • 尚未招聘
        • CHRU de Tours - Hôpital Bretonneau - Médecine Intensive Réanimation
    • Grand Est
      • Strasbourg、Grand Est、法国、67091
        • 招聘中
        • Hopitaux Universitaires de Strasbourg Nouvel Hopital Civil - Service de Médecine Intensive Réanimation
    • New Aquitaine
      • Limoges、New Aquitaine、法国、87042
        • 招聘中
        • Centre Hospitalier Universitaire de Limoges Dupuytren 1 - Service de réanimation polyvalente
    • Pays de la Loire Region
      • Angers、Pays de la Loire Region、法国、49100
        • 招聘中
        • Centre Hospitalier Universitaire d'Angers - Médecine Intensive Réanimation et Médecine Hyperbare
      • La Roche-sur-Yon、Pays de la Loire Region、法国、85000
        • 招聘中
        • Centre Hospitalier Départemental Vendée - Service de réanimation polyvalente
      • Nantes、Pays de la Loire Region、法国、44000
        • 招聘中
        • Hopital Hotel Dieu Nantes - Service de Médecine Intensive Réanimation
    • Île-de-France Region
      • Garches、Île-de-France Region、法国、92380
        • 尚未招聘
        • Hôpital Raymond-Poincaré - Service de Médecine Intensive - Réanimation, Médecine Hyperbare
    • Colorado
      • Aurora、Colorado、美国、80045
        • 尚未招聘
        • UC Health University of Colorado Hospital - Medical Intensive Care Unit
    • Gelderland
      • Nijmegen、Gelderland、荷兰、6525 GA
        • 尚未招聘
        • Universitair Medisch Centrum St. Radboud - Intensive Care
      • Nijmegen、Gelderland、荷兰、6532 SZ
        • 尚未招聘
        • Canisius WIlhelmina Ziekenhuis - Intensive Care
    • North Brabant
      • 's-Hertogenbosch、North Brabant、荷兰、5223 GZ
        • 尚未招聘
        • Jeroen Bosch Ziekenhuis - Intensive Care
    • Overijssel
      • Enschede、Overijssel、荷兰、7512 KZ
        • 尚未招聘
        • Medisch Spectrum Twente - Intensive Care
    • South Holland
      • Rotterdam、South Holland、荷兰、3015 GD
        • 尚未招聘
        • Erasmus Medisch Centrum - Intensive Care

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 85年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Participant must be ≥ 18 and ≤ 85 years of age at the time of signing the informed consent.
  • Participants with diagnosed sepsis according to sepsis-3 criteria. Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection.
  • participants with suspected or documented origin of infection.
  • Participants with coagulopathy defined by at least one of the following within 24 hours prior start of study intervention: INR ≥1.40, platelet count in the range of ≥ 30,000/mm3 to < 150,000/mm3 OR greater than 30% decrease in platelets in 24 hours without other known etiology. The platelet count after decrease should not be < 30,000/mm3.
  • Participants must be receiving treatment in an ICU.
  • Informed consent of capable participant or, in case of participant being incapable of giving informed consent, consent for study inclusion will be sought according to applicable laws and regulations.

Exclusion Criteria:

  • Clinically significant active bleeding; known bleeding disorder, history of major traumatic or non-traumatic bleeding (intracranial, retroperitoneal, intraocular) or clinically significant gastrointestinal bleeding within last 6 months.

  • Low platelets level or abnormal coagulation status due to any other reason than sepsis.

  • Participants with indication for therapeutic dose of: anticoagulation (heparin, argatroban, vitamin K antagonists/warfarin, dabigatran, apixaban, rivaroxaban, edoxaban), oral antiplatelet agents (clopidogrel, ticagrelor, ticlopidine, prasugrel) except low dose (≤100mg) acetyl salicylic acid (ASA), digoxin, metformin

  • Participants with:

    1. Uncontrolled malignancy requiring ongoing chemotherapy, radiation therapy, or immunotherapy within the past 6 months with the exception of: low-risk localized prostate cancer (Gleason score is equal to or less than 6 AND Prostate- Specific Antigen is below 10 ng/mL); or cervical carcinoma in situ; or ductal carcinoma in situ; or adequately treated non-metastatic squamous cell skin carcinoma; or adequately treated basal cell skin carcinoma. Patients with breast or prostate cancer receiving single endocrine (hormonal) therapy are eligible if all other cancer-directed treatments were completed more than 6 months prior to screening
    2. Any hematological malignancy
    3. Any active or prior malignancy involving the central nervous system (brain or spinal cord), including primary tumors or metastases.
  • Pregnancy or breastfeeding.

  • Chronic liver disease Child-Pugh Class C.

  • Participants experienced major surgery or major trauma (intrathoracic, intra-abdominal, pelvic or femur) or surgery/trauma in any other area with potentially clinically significant consequences due to bleeding within 28 days before study drug administration.

  • Participants experienced neurotrauma or neurosurgery (brain, spine) or orthopedic surgery in spine within 6 months before study drug administration

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:非随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Cohort 1 of BAY3389934

Subjects will receive titrated dose of BAY3389934 as continuous infusion over up to 96 hours.

Solution for IV infusion

实验性的:Cohort 2 of BAY3389934

Subjects will receive titrated dose of BAY3389934 as continuous infusion over up to 96 hours.

Solution for IV infusion

研究衡量的是什么?

主要结果指标

结果测量
大体时间
有TEAES的参与者人数(治疗伴随不良事件)
大体时间:在研究干预后首次进行研究干预措施后1小时后,最多97小时
在研究干预后首次进行研究干预措施后1小时后,最多97小时
茶的严重程度
大体时间:在研究干预后首次进行研究干预措施后1小时后,最多97小时
在研究干预后首次进行研究干预措施后1小时后,最多97小时

次要结果测量

结果测量
大体时间
激活的部分凝血活蛋白时间(APTT)
大体时间:从研究干预第1天的第一个管理到第6天
从研究干预第1天的第一个管理到第6天
凝血酶原时间(PT)
大体时间:从研究干预第1天的第一个管理到第6天
从研究干预第1天的第一个管理到第6天

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年3月12日

初级完成 (估计的)

2026年12月25日

研究完成 (估计的)

2027年1月17日

研究注册日期

首次提交

2025年2月28日

首先提交符合 QC 标准的

2025年2月28日

首次发布 (实际的)

2025年3月3日

研究记录更新

最后更新发布 (实际的)

2026年11月10日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年10月28日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅